Please wait a minute...
文章检索
预防医学  2026, Vol. 38 Issue (9): 963-966    DOI: 10.19485/j.cnki.issn2096-5087.2026.09.022
  卫生管理 本期目录 | 过刊浏览 | 高级检索 |
湖州市结核分枝杆菌潜伏感染预防性治疗策略与实践
任飞林1, 杨中荣1, 孙秀秀1, 张思潮1, 金玫华1, 沈建勇1, 丁忠明1, 闻栋2, 郑平明2, 张鹏1
1.湖州市疾病预防控制中心,浙江 湖州 313000;
2.湖州市卫生健康委员会,浙江 湖州 313000
Strategies and practices of tuberculosis preventive treatment for latent tuberculosis infection in Huzhou City
REN Feilin1, YANG Zhongrong1, SUN Xiuxiu1, ZHANG Sichao1, JIN Meihua1, SHEN Jianyong1, DING Zhongming1, WEN Dong2, ZHENG Pingming2, ZHANG Peng1
1. Huzhou Center for Disease Control and Prevention, Huzhou, Zhejiang 313000, China;
2. Huzhou Municipal Health Commission, Huzhou, Zhejiang 313000, China
全文: PDF(847 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 世界卫生组织(WHO)强调预防性治疗是终结结核病流行的关键措施,2023年湖州市在浙江省无结核社区试点基础上启动无结核城市建设,构建市、县(区)和乡镇(街道)三级结核分枝杆菌潜伏感染(LTBI)预防性治疗体系。通过制定标准和规范、推广各级预防性治疗门诊、完善人员配备和明确工作职责等策略,加强LTBI主动干预与管理、提升预防性治疗规范化水平。2023—2024年湖州市检出结核分枝杆菌(MTB)阳性27 535例,预防性治疗接受率为34.82%,完成率为57.89%。随访发现,未接受预防治疗的MTB阳性者活动性肺结核发病密度为393.83/10万人年,接受预防性治疗但中断治疗者发病密度为293.83/10万人年,接受预防性治疗并完成治疗者发病密度为46.08/10万人年。实践表明,湖州市构建LTBI预防性治疗体系可及性强、实操性高,有效扩大了高危人群干预覆盖面,能够显著降低MTB阳性者的活动性肺结核发病风险,为全国开展LTBI防控工作提供可复制、可推广的实践范式。未来湖州市将持续依托基层医疗卫生机构,优化LTBI全流程规范化管理;依托智慧化防控技术,优化诊疗服务与跨区域联动机制,持续巩固无结核城市建设成效,稳步降低区域结核病疫情,助力实现终结结核病流行战略目标。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
任飞林
杨中荣
孙秀秀
张思潮
金玫华
沈建勇
丁忠明
闻栋
郑平明
张鹏
关键词 : 结核分枝杆菌潜伏感染,  结核病预防性治疗,  预防性治疗体系,  无结核城市    
Abstract:The World Health Organization (WHO) emphasizes that tuberculosis preventive treatment is a key measure for ending the tuberculosis epidemic. In 2023, Huzhou City initiated the construction of Zero Tuberculosis City based on the pilot program of Zero Tuberculosis Communities in Zhejiang Province, and established a three-level tuberculosis preventive treatment system for latent tuberculosis infection (LTBI) at the municipal, county (district), and township (subdistrict) levels. Strategies including formulating standards and norms, promoting preventive treatment clinics at all levels, improving staffing and clarifying work responsibilities were implemented to strengthen active intervention and management of LTBI and improve the standardization of preventive treatment. From 2023 to 2024, a total of 27 535 individuals tested positive for Mycobacterium tuberculosis (MTB) in Huzhou City. The acceptance rate of preventive treatment was 34.82%, and the completion rate was 57.89%. During follow-up, the incidence density of active pulmonary tuberculosis among MTB-positive individuals who did not receive preventive treatment was 393.83/105 person-years, while that among individuals who received preventive treatment but interrupted treatment was 293.83/105 person-years, and that among individuals who received and completed preventive treatment was 46.08/105 person-years. Practices have shown that the LTBI preventive treatment system constructed in Huzhou City features strong accessibility and high operability, which has effectively expanded the coverage of interventions for high-risk groups, significantly reduced the risk of active pulmonary tuberculosis among MTB-positive individuals, and provided a replicable and promotable practical paradigm for LTBI prevention and control nationwide. In the future, Huzhou City will continue to rely on the primary medical and health network to optimize the whole-process standardized management of LTBI, leverage smart prevention and control technologies, optimize diagnosis and treatment services and cross-regional linkage mechanisms, continuously consolidate the achievements of the Zero Tuberculosis City initiative, steadily reduce the regional tuberculosis epidemic, and contribute to the achievement of the strategic goal of ending the tuberculosis epidemic.
Key words: latent tuberculosis infection    tuberculosis preventive treatment    preventive treatment system    Zero Tuberculosis City
收稿日期: 2026-03-26      修回日期: 2026-09-05     
中图分类号:  R52  
基金资助:浙江省疾病预防控制科技计划项目(2025JK282); 浙江省疾病预防控制创新培育团队(2026JKP-06); 新发突发与重大传染病防控国家科技重大专项(2025ZD01901004)
作者简介: 任飞林,硕士,主管医师,主要从事传染病监测与控制工作
通信作者: 张鹏,E-mail:hzjkzp@163.com   
引用本文:   
任飞林, 杨中荣, 孙秀秀, 张思潮, 金玫华, 沈建勇, 丁忠明, 闻栋, 郑平明, 张鹏. 湖州市结核分枝杆菌潜伏感染预防性治疗策略与实践[J]. 预防医学, 2026, 38(9): 963-966.
REN Feilin, YANG Zhongrong, SUN Xiuxiu, ZHANG Sichao, JIN Meihua, SHEN Jianyong, DING Zhongming, WEN Dong, ZHENG Pingming, ZHANG Peng. Strategies and practices of tuberculosis preventive treatment for latent tuberculosis infection in Huzhou City. Preventive Medicine, 2026, 38(9): 963-966.
链接本文:  
https://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2026.09.022      或      https://www.zjyfyxzz.com/CN/Y2026/V38/I9/963
[1] Hartman-Adams H,Clark K,Juckett G.Update on latent tuberculosis infection[J].Am Fam Physician,2014,89(11):889-896.
[2] Zenner D,Beer N,Harris R J,et al.Treatment of latent tuberculosis infection:an updated network meta-analysis[J].Ann Intern Med,2017,167(4):248-255.
[3] World Health Organization.WHO consolidated guidelines on tuberculosis:module 1:prevention-tuberculosis preventive treatment second section[R].Geneva:WHO,2024.
[4] 徐彩红,赵雁林.中国结核病预防性治疗指南[M].北京:人民卫生出版社,2023.
[5] 湖州市卫生健康委员会.湖州市结核病防治管理办法[Z].2013.
[6] 吴倩,王伟,张钰,等.浙江省无结核社区评价指标体系构建[J].中国防痨杂志,2025,47(3):331-337.
[7] 郑平明,金玫华,丁忠明,等.浙江省湖州市“无结核城市”建设实践与思考[J].中国防痨杂志,2024,46(10):1193-1197.
[8] 湖州市卫生健康委员会办公室.湖州市卫生健康委办公室关于印发结核病预防性治疗门诊建设标准的通知[Z].2023.
[9] 湖州市疾病预防控制中心.关于印发湖州市结核病预防性治疗对象社区随访服务规范(试行)的通知[Z].2024.
[10] T/CHATA 028—2022 结核分枝杆菌潜伏感染人群预防性治疗规范[S].
[11] T/CHATA 052—2025 基层医疗卫生机构结核病预防性治疗门诊建设规范[S].
[12] 马艳,陆伟,高磊,等.终止结核病流行须加强结核分枝杆菌潜伏感染高危人群筛查和预防性治疗的管理[J].中国防痨杂志,2022,44(3):209-214.
[13] 丁厅厅,许兴龙,李霞,等.基层医疗卫生机构开设结核病预防性治疗门诊的SWOT分析[J].中国卫生质量管理,2025,32(9):107-110.
[14] 肖筱,陈彬,刘巧,等.我国结核分枝杆菌潜伏感染筛查与预防性治疗进展[J].预防医学,2026,38(5):433-437.
[15] 中华人民共和国国家疾病预防控制局,中华人民共和国国家卫生健康委员会,中华人民共和国国家发展和改革委员会,等.关于印发全国结核病防治规划(2024—2030年)的通知[EB/OL].[2026-09-05].https://www.gov.cn/zhengce/zhengceku/202412/content_6991217.htm.
[16] 陈彬.关口前移,创新驱动,迈向终结结核流行[J].预防医学,2026,38(3):217-221.
[1] 熊燕, 夏岚, 李运葵, 钟引, 王丹霞, 李婷. 四川省肺结核患者密切接触者筛查结果分析[J]. 预防医学, 2026, 38(7): 666-670.
[2] 赵丽娜, 曾真, 林韩特, 毛景, 朱婷婷, 单志力, 毛玲琼, 李君. 温州市HIV/AIDS病例结核分枝杆菌潜伏感染分析[J]. 预防医学, 2026, 38(6): 550-554.
[3] 杨利, 滕楠, 张若娣, 陈腾伟, 许圆圆. 台州市中小学生结核分枝杆菌潜伏感染筛查结果[J]. 预防医学, 2026, 38(6): 564-567.
[4] 陈国智, 赵丽娜. 结核分枝杆菌潜伏感染检测技术与诊断的研究进展[J]. 预防医学, 2026, 38(5): 447-451.
[5] 肖筱, 陈彬, 刘巧, 沈鑫. 我国结核分枝杆菌潜伏感染筛查与预防性治疗进展[J]. 预防医学, 2026, 38(5): 433-437.
[6] 张业晴, 于全骥, 刘巧. 江苏省结核分枝杆菌潜伏感染防治策略、实践与挑战[J]. 预防医学, 2026, 38(5): 438-441.
[7] 朱珂, 陈高尚, 唐慧玲, 龙智平, 金屡华, 吴佳晖. 金华市HIV/AIDS病例结核分枝杆菌潜伏感染的影响因素分析[J]. 预防医学, 2026, 38(5): 452-455.
[8] 孟祥杰, 唐崟, 寿钧, 孙明希, 张钰. 余杭区中学生结核分枝杆菌潜伏感染调查[J]. 预防医学, 2026, 38(5): 456-459,463.
[9] 曾真, 赵丽娜, 单志力, 毛景, 林韩特, 毛玲琼, 李君. 温州市企业职工结核分枝杆菌潜伏感染调查[J]. 预防医学, 2026, 38(4): 334-337.
[10] 张文, 吴成果, 郑登虎, 罗建奎, 罗杰, 孙建, 张理翌, 雷蓉蓉, 廖文平. 南川区老年人群结核分枝杆菌潜伏感染调查[J]. 预防医学, 2026, 38(4): 338-342.
[11] 刘扬, 陈莉莉, 辛辛, 肖绍坦, 李世宏. 浦东新区高校肺结核密切接触学生结核分枝杆菌潜伏感染的影响因素研究[J]. 预防医学, 2026, 38(3): 226-230.
[12] 吕阳, 乐博昕, 胡伟宏, 刘园, 陈昶, 刘效峰. 肺结核密切接触学生结核分枝杆菌潜伏感染的影响因素分析[J]. 预防医学, 2024, 36(8): 658-662.
[13] 王慧, 李锦成, 陆兴, 王金富, 竺丽梅, 刘巧. 重组结核杆菌融合蛋白皮肤试验筛查HIV/AIDS病例结核分枝杆菌潜伏感染的效果分析[J]. 预防医学, 2024, 36(7): 639-643.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed